vs
ASGN Inc（ASGN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
ASGN Inc的季度营收约是Royalty Pharma plc的1.6倍（$970.0M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 0.6%，领先33.9%），Royalty Pharma plc同比增速更快（4.8% vs -3.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -3.2%）
ASGN Inc是总部位于美国的领先专业服务与人力资源解决方案供应商，主营信息技术、创意设计、生命科学、工程等领域的技术人才供给及咨询服务，主要服务北美地区的企业级客户。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
ASGN vs RPRX — 直观对比
营收规模更大
ASGN
是对方的1.6倍
$622.0M
营收增速更快
RPRX
高出7.8%
-3.0%
净利率更高
RPRX
高出33.9%
0.6%
两年增速更快
RPRX
近两年复合增速
-3.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $970.0M | $622.0M |
| 净利润 | $5.5M | $214.2M |
| 毛利率 | 27.5% | — |
| 营业利润率 | 2.9% | 62.4% |
| 净利率 | 0.6% | 34.4% |
| 营收同比 | -3.0% | 4.8% |
| 净利润同比 | -73.7% | 2.9% |
| 每股收益（稀释后） | $0.13 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASGNRPRX
| Q1 26 | $970.0M | — | ||
| Q4 25 | $980.1M | $622.0M | ||
| Q3 25 | $1.0B | $609.3M | ||
| Q2 25 | $1.0B | $578.7M | ||
| Q1 25 | $968.3M | $568.2M | ||
| Q4 24 | $985.0M | $593.6M | ||
| Q3 24 | $1.0B | $564.7M | ||
| Q2 24 | $1.0B | $537.3M |
净利润ASGNRPRX
| Q1 26 | $5.5M | — | ||
| Q4 25 | $25.2M | $214.2M | ||
| Q3 25 | $38.1M | $288.2M | ||
| Q2 25 | $29.3M | $30.2M | ||
| Q1 25 | $20.9M | $238.3M | ||
| Q4 24 | $42.4M | $208.2M | ||
| Q3 24 | $47.5M | $544.0M | ||
| Q2 24 | $47.2M | $102.0M |
毛利率ASGNRPRX
| Q1 26 | 27.5% | — | ||
| Q4 25 | 28.9% | — | ||
| Q3 25 | 29.4% | — | ||
| Q2 25 | 28.7% | — | ||
| Q1 25 | 28.4% | — | ||
| Q4 24 | 29.0% | — | ||
| Q3 24 | 29.1% | — | ||
| Q2 24 | 29.1% | — |
营业利润率ASGNRPRX
| Q1 26 | 2.9% | — | ||
| Q4 25 | 5.7% | 62.4% | ||
| Q3 25 | 6.7% | 70.1% | ||
| Q2 25 | 5.8% | 36.3% | ||
| Q1 25 | 4.8% | 94.0% | ||
| Q4 24 | 7.5% | 60.9% | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.8% | 50.2% |
净利率ASGNRPRX
| Q1 26 | 0.6% | — | ||
| Q4 25 | 2.6% | 34.4% | ||
| Q3 25 | 3.8% | 47.3% | ||
| Q2 25 | 2.9% | 5.2% | ||
| Q1 25 | 2.2% | 41.9% | ||
| Q4 24 | 4.3% | 35.1% | ||
| Q3 24 | 4.6% | 96.3% | ||
| Q2 24 | 4.6% | 19.0% |
每股收益（稀释后）ASGNRPRX
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.58 | $0.49 | ||
| Q3 25 | $0.87 | $0.67 | ||
| Q2 25 | $0.67 | $0.07 | ||
| Q1 25 | $0.48 | $0.55 | ||
| Q4 24 | $0.94 | $0.46 | ||
| Q3 24 | $1.06 | $1.21 | ||
| Q2 24 | $1.02 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $143.6M | $618.7M |
| 总债务越低越好 | $1.5B | $9.0B |
| 股东权益账面价值 | $1.8B | $9.7B |
| 总资产 | $4.0B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.82× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资ASGNRPRX
| Q1 26 | $143.6M | — | ||
| Q4 25 | $161.2M | $618.7M | ||
| Q3 25 | — | $938.9M | ||
| Q2 25 | — | $631.9M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | $205.2M | $929.0M | ||
| Q3 24 | — | $950.1M | ||
| Q2 24 | — | $1.8B |
总债务ASGNRPRX
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.2B | $9.0B | ||
| Q3 25 | $1.2B | $8.9B | ||
| Q2 25 | $1.2B | $8.0B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.0B | $7.6B | ||
| Q3 24 | $1.0B | $7.6B | ||
| Q2 24 | $1.0B | $7.6B |
股东权益ASGNRPRX
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $9.7B | ||
| Q3 25 | $1.8B | $9.6B | ||
| Q2 25 | $1.8B | $9.5B | ||
| Q1 25 | $1.8B | $9.8B | ||
| Q4 24 | $1.8B | $10.3B | ||
| Q3 24 | $1.8B | $10.3B | ||
| Q2 24 | $1.8B | $9.8B |
总资产ASGNRPRX
| Q1 26 | $4.0B | — | ||
| Q4 25 | $3.7B | $19.6B | ||
| Q3 25 | $3.7B | $19.3B | ||
| Q2 25 | $3.7B | $18.3B | ||
| Q1 25 | $3.7B | $17.6B | ||
| Q4 24 | $3.4B | $18.2B | ||
| Q3 24 | $3.4B | $18.0B | ||
| Q2 24 | $3.5B | $17.7B |
负债/权益比ASGNRPRX
| Q1 26 | 0.82× | — | ||
| Q4 25 | 0.65× | 0.92× | ||
| Q3 25 | 0.64× | 0.93× | ||
| Q2 25 | 0.66× | 0.84× | ||
| Q1 25 | 0.72× | 0.78× | ||
| Q4 24 | 0.58× | 0.74× | ||
| Q3 24 | 0.58× | 0.74× | ||
| Q2 24 | 0.57× | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $9.1M | — |
| 自由现金流率自由现金流/营收 | 0.9% | — |
| 资本支出强度资本支出/营收 | 1.0% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $290.6M | — |
8季度趋势，按日历期对齐
经营现金流ASGNRPRX
| Q1 26 | — | — | ||
| Q4 25 | $102.3M | $827.1M | ||
| Q3 25 | $83.9M | $702.6M | ||
| Q2 25 | $124.9M | $364.0M | ||
| Q1 25 | $16.8M | $596.1M | ||
| Q4 24 | $100.2M | $742.5M | ||
| Q3 24 | $135.8M | $703.6M | ||
| Q2 24 | $90.7M | $658.2M |
自由现金流ASGNRPRX
| Q1 26 | $9.1M | — | ||
| Q4 25 | $93.7M | — | ||
| Q3 25 | $72.0M | — | ||
| Q2 25 | $115.8M | — | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $88.9M | — | ||
| Q3 24 | $127.9M | — | ||
| Q2 24 | $85.4M | — |
自由现金流率ASGNRPRX
| Q1 26 | 0.9% | — | ||
| Q4 25 | 9.6% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 11.3% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 12.4% | — | ||
| Q2 24 | 8.3% | — |
资本支出强度ASGNRPRX
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.1% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.5% | — |
现金转化率ASGNRPRX
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 3.86× | ||
| Q3 25 | 2.20× | 2.44× | ||
| Q2 25 | 4.26× | 12.06× | ||
| Q1 25 | 0.80× | 2.50× | ||
| Q4 24 | 2.36× | 3.57× | ||
| Q3 24 | 2.86× | 1.29× | ||
| Q2 24 | 1.92× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASGN
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
